Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865339 | 0.83 | POLB (0.45) | SMN1; SMN2PPIDALDH1A1GAAMAPT | |
| SCHEMBL9198556 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2PPIDALDH1A1GAAMAPT | |
| SCHEMBL6867000 | 0.83 | CCR1 (0.40) | SMN1; SMN2PPIDGAAMAPTTDP1 | |
| SCHEMBL6867009 | 0.83 | BCHE (0.43) | SMN1; SMN2PPIDALDH1A1GAAMAPT | |
| SCHEMBL11662107 | 0.74 | SIGMAR1 (0.40) | SMN1; SMN2PPIDGAA | |
| SCHEMBL15075052 | 0.69 | CCR1 (0.41) | SMN1; SMN2ALDH1A1MAPTTDP1TSHR | |
| SCHEMBL21027095 | 0.68 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1GAAMAPTTSHR | |
| SCHEMBL12745105 | 0.67 | KCNH2 (0.36) | SMN1; SMN2ALDH1A1GAAMAPTTDP1 | |
| SCHEMBL24981178 | 0.67 | ALDH1A1 (0.44) | PPIDALDH1A1GAAMAPTTSHR | |
| SCHEMBL17051306 | 0.67 | APEX1 (0.47) | PPIDALDH1A1GAAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806283-B2 | SUCH AS SPIRO(9,10-DIHYDROANTHRACENE)-9,3'-PYRROLIDINE; FOR USE AS ANTIDEPRESSANT AND ANTIANXIETY AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2004-10-19 | — | — | US | disclosed |
| US-20030232872-A1 | Selective serotonin receptor antagonists and therapeutic applications thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232872-A1 | Selective serotonin receptor antagonists and therapeutic applications thereof | HTR2A, HTR7, HTR1A | SMN1; SMN2 1356/4885PPID 839/4885ALDH1A1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.